Flurandrenolide Brand Names

Cordran | Cordran SP | Cordran Tape | Nolix

What is Flurandrenolide

Flurandrenolide is a fluorinated, low- to medium-potency, topical corticosteroid. It is available in cream, lotion, ointment or impregnated tape formulation.

The impregnated tape is useful for occlusive therapy of small areas. Low potency products contain flurandrenolide in concentrations less than 0.25%. The drug is used for symptomatic treatment of corticosteroid-responsive skin disorders characterized by inflammation and/or pruritus such as seborrheic dermatitis, atopic dermatitis, and psoriasis.

Fluorinated corticosteroid compounds allow for treating affected areas with thicker skin such as the palms and soles.

Flurandrenolide application should be avoided, if possible, on areas of thinner skin, such as the face and intertriginous areas, because of potential toxicities inherent in fluorinated compounds.

Flurandrenolide was first approved by the FDA in 1963.


  1. alopecia
  2. atopic dermatitis
  3. contact dermatitis
  4. dermatitis
  5. discoid lupus erythematosus
  6. eczema
  7. exfoliative dermatitis
  8. granuloma annulare
  9. lichen planus
  10. lichen simplex
  11. pompholyx
  12. prurigo
  13. pruritus
  14. psoriasis
  15. Rhus dermatitis
  16. seborrheic dermatitis
  17. xerosis

Side Effects

  1. acneiform rash
  2. adrenocortical insufficiency
  3. cataracts
  4. contact dermatitis
  5. Cushing’s syndrome
  6. erythema
  7. folliculitis
  8. glycosuria
  9. growth inhibition
  10. headache
  11. hyperglycemia
  12. hypertension
  13. hypertrichosis
  14. hypothalamic-pituitary-adrenal (HPA) suppression
  15. impaired wound healing
  16. increased intracranial pressure
  17. infection
  18. maculopapular rash
  19. miliaria
  20. ocular hypertension
  21. papilledema
  22. pruritus
  23. pseudotumor cerebri
  24. purpura
  25. skin atrophy
  26. skin hypopigmentation
  27. skin irritation
  28. skin ulcer
  29. striae
  30. telangiectasia
  31. tolerance
  32. visual impairment
  33. withdrawal
  34. xerosis

Monitoring Parameters

  • laboratory monitoring not necessary


  • acne rosacea
  • acne vulgaris
  • breast-feeding
  • children
  • Cushing’s syndrome
  • diabetes mellitus
  • fungal infection
  • geriatric
  • growth inhibition
  • herpes infection
  • hypothalamic-pituitary-adrenal (HPA) suppression
  • increased intracranial pressure
  • infants
  • infection
  • measles
  • neonates
  • occlusive dressing
  • ocular exposure
  • ophthalmic administration
  • perioral dermatitis
  • peripheral vascular disease
  • pregnancy
  • skin abrasion
  • skin atrophy
  • tuberculosis
  • varicella
  • viral infection


  • Metyrapone

Metyrapone: (Major) Medications which affect pituitary or adrenocortical function, including all corticosteroid therapy, should be discontinued prior to and during testing with metyrapone. Patients taking inadvertent doses of corticosteroids on the test day may exhibit abnormally high basal plasma cortisol levels and a decreased response to the test. Although systemic absorption of topical corticosteroids is minimal, temporary discontinuation of these products should be considered if possible to reduce the potential for interference with the test results.